In this setting, therapeutic blockade of PD-L1 will help unleash the reactivity of PD-L1-expressing NK cells against MHC-Ilow tumors [290], while also improving antigen presentation in the tumor microenvironment [347]. This evidence concerns the gene CD274 and neoplasm.